Active Ingredient History
Lofexidine is newly FDA approved in the United States under the brand name LUCEMYRA for the treatment of opioid withdrawal symptoms in adults. Lofexidine acts as an agonist to α2 adrenergic receptors. These receptors inhibit adenylyl cyclase activity, leading to the inhibition of the second messenger, cyclic adenosine monophosphate (cAMP). The inhibition of cAMP leads to potassium efflux through calcium-activated channels, blocking calcium ions from entering the nerve terminal, resulting in suppression of neural firing, inhibition of norepinephrine release. Lofexidine replaces the opioid-driven inhibition of cAMP production and moderating the symptoms of opioid withdrawal. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Opioid-Related Disorders (approved 2018)
Analgesics, Opioid (Phase 4)
Cocaine-Related Disorders (Phase 1)
Healthy Volunteers (Phase 1)
Heroin Dependence (Phase 1)
Kidney Diseases (Phase 1)
Liver Failure (Phase 1)
Marijuana Abuse (Phase 2/Phase 3)
Opiate Overdose (Phase 4)
Opioid-Related Disorders (Phase 3)
Stress Disorders, Post-Traumatic (Phase 2)
Substance-Related Disorders (Phase 1)
Substance Withdrawal Syndrome (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
